Jupiter Neurosciences (JUNS) has entered into a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100M Jupiter will make an upfront payment of $3.3M, including
Jupiter Neurosciences (JUNS) has entered into a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002.
The transaction has a potential value of up to $100M
Jupiter will make an upfront payment of $3.3M, including $1.5M cash and $1.8M in
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
